UnitedHealth's strong recent execution underpins the 85.5% market-implied probability of beating Q3 2026 non-GAAP EPS consensus near $4.12–$4.14. The company delivered a sizable Q2 beat with $6.38 adjusted EPS against estimates around $4.9, alongside revenue of $112 billion, prompting an upward revision of full-year 2026 adjusted EPS guidance to $19.50–$20.00. Margin recovery in Medicare Advantage and Optum Health, aided by lower medical cost ratios and favorable reimbursement trends, has sustained momentum into September, as noted in recent investor conferences. With the earnings release set for October 13, trader consensus reflects these operational tailwinds and a track record of beats, though sustained utilization or regulatory shifts could still influence the outcome.